6 completed, 2 active not recruiting. 8 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 8 | Completed 6, Active not recruiting 2 |
Follow Recurrent Uterine Corpus Carcinoma: new trials by email Literature Review of Recurrent Uterine Corpus Carcinoma trials Research Report on Recurrent Uterine Corpus Carcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Mirvetuximab Soravtansine and Rucaparib Camsylate in Treating Participants With Recurrent Endometrial, Ovarian, Fallopian Tube or Primary Peritoneal Cancer Laboratory Biomarker Analysis, Mirvetuximab Soravtansine, Pharmacokinetic Study - BRCA1 Gene Mutation, BRCA2 Gene Mutation | Phase 1 | Completed | Ohio State University Comprehensive Cancer Center | 25 | 2018-07-12 | 2025-02-13 |
| Mirvetuximab Soravtansine and Gemcitabine Hydrochloride in Treating Patients With FRalpha-Positive Recurrent Ovarian, Primary Peritoneal, Fallopian Tube, Endometrial, or Triple Negative Breast Cancer Gemcitabine, Gemcitabine Hydrochloride, Laboratory Biomarker Analysis - Recurrent Breast Carcinoma, Recurrent Fallopian Tube Carcinoma | Phase 1 | Completed | City of Hope Medical Center | 44 | 2017-10-02 | 2026-10-01 |
| mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and Ovarian Capivasertib, Laboratory Biomarker Analysis, Olaparib - BRCA1 Mutation Carrier, BRCA2 Mutation Carrier | Phase 1 | Active not recruiting | M.D. Anderson Cancer Center | 159 | 2014-11-11 | 2026-09-04 |
| Surgery and Chemotherapy With or Without Chemotherapy After Surgery in Treating Patients With Ovarian, Fallopian Tube, Uterine, or Peritoneal Cancer Carboplatin, Cisplatin, Gemcitabine Hydrochloride - FIGO Stage IVA Ovarian Cancer, FIGO Stage IVB Ovarian Cancer | Phase 1 | Active not recruiting | City of Hope Medical Center | 40 | 2014-07-01 | 2026-10-26 |
| Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Laboratory Biomarker Analysis, Pharmacological Study - Anaplastic Astrocytoma, Anaplastic Oligoastrocytoma | Phase 1 | Completed | Roswell Park Cancer Institute | 18 | 2012-03-01 | 2016-10-04 |
| Dasatinib, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV or Recurrent Endometrial Cancer Carboplatin, Dasatinib, Laboratory Biomarker Analysis - Endometrial Adenocarcinoma, Endometrial Clear Cell Adenocarcinoma | Phase 1 | Completed | National Cancer Institute (NCI) | 18 | 2011-09-20 | 2018-04-05 |
| Intraperitoneal Paclitaxel, Doxorubicin Hydrochloride, and Cisplatin in Treating Patients With Stage III-IV Endometrial Cancer Cisplatin, Doxorubicin Hydrochloride, Filgrastim - Endometrial Adenosquamous Carcinoma, Endometrial Clear Cell Adenocarcinoma | Phase 1 | Completed | Gynecologic Oncology Group | 27 | 2008-01-17 | 2017-08-24 |
| Eribulin Mesylate and Gemcitabine Hydrochloride in Treating Patients With Metastatic Solid Tumors or Solid Tumors That Cannot be Removed by Surgery Eribulin Mesylate, Gemcitabine Hydrochloride - Adult Solid Neoplasm, Recurrent Ovarian Carcinoma | Phase 1 | Completed | National Cancer Institute (NCI) | 45 | 2006-11-14 | 2018-10-03 |
Ovarian Neoplasms (6) · Fallopian Tube Neoplasms (4) · Breast Neoplasms (3) · Triple Negative Breast Neoplasms (2) · Astrocytoma (1) · Brain Neoplasms (1) · Carcinoma, Endometrioid (1) · Carcinoma, Hepatocellular (1) · Carcinoma, Renal Cell (1) · Colorectal Neoplasms (1) · Esophageal Neoplasms (1) · Glioblastoma (1) · Lung Neoplasms (1) · Melanoma (1) · Oligodendroglioma (1)
Adnexal Diseases (7) · Endocrine System Diseases (7) · Female Urogenital Diseases (7) · Female Urogenital Diseases and Pregnancy Complications (7) · Genital Diseases (7) · Genital Diseases, Female (7) · Genital Neoplasms, Female (7) · Gonadal Disorders (7) · Neoplasms (7) · Neoplasms by Site (7) · Ovarian Diseases (7) · Urogenital Diseases (7) · Urogenital Neoplasms (7) · Endocrine Gland Neoplasms (6) · Fallopian Tube Diseases (4)
Gemcitabine (3) · Paclitaxel (3) · Carboplatin (2) · Cisplatin (2) · Doxorubicin (2) · Taxes (2) · mirvetuximab soravtansine (2) · 1,2-diaminocyclohexaneplatinum II citrate (1) · Dasatinib (1) · Filgrastim (1) · Pharmacogenomic Variants (1) · Platinum (1) · Sirolimus (1) · capivasertib (1) · eribulin (1)
City of Hope Medical Center (2) · National Cancer Institute (NCI) (2) · Gynecologic Oncology Group (1) · M.D. Anderson Cancer Center (1) · Ohio State University Comprehensive Cancer Center (1) · Roswell Park Cancer Institute (1)
United States (7) · Canada (1)
D. McMeekin (1) · Edward W Wang (1) · Floor Backes, MD (1) · Kunle Odunsi (1) · Rakesh Goel (1) · Robert Coleman (1) · Shannon N Westin (1) · Thanh Dellinger (1)
PMID 26554651, PMID 32379297, PMID 35357903, PMID 40132910
N01CM00032 (1), N01CM17107 (1), P30CA016056 (1), P30CA016672 (1), P50CA083639 (1), P50CA098258 (1), R01CA158318 (1), U10CA027469 (1), U10CA180868 (1)